Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07251413Phase 1Recruiting

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

Role: lead

NCT04487756Phase 1Active Not Recruiting

Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Role: lead

NCT04772235Phase 1Recruiting

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Role: lead

NCT03623750Phase 1Completed

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Role: lead

NCT04537130Phase 1Unknown

Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge

Role: lead

All 5 trials loaded